FDA Rejects T1D Delayer; Sticker Shock for Wegovy; Oral FMT for Insulin Sensitivity

The FDA turned down Provention Bio’s teplizumab — an investigative treatment to delay type 1 diabetes in people at a higher genetic risk — for approval, citing concerns over pharmacokinetic comparability.

A small study found that impulsive and extroverted kids were more likely to be speed-eaters, possibly putting them at higher risk for obesity. (ScienceDaily)

Coming in at the high price of $1,000 to $1,500 per month, will the newly approved obesity drug Wegovy (injectable semaglutide 2.4 mg) be covered by insurance? (NPR)

Adding to previous research, a new study presented at the European Association of Urology virtual congress found that men with low testosterone and symptomatic COVID-19 were at a higher risk for severe infection and death.

A randomized phase II trial found that single-dose oral fecal microbial transplantation plus daily low-fermentable fiber significantly improved insulin sensitivity in those with severe obesity and metabolic syndrome. (Nature Medicine)

Women exposed to greater levels of air pollution — specifically elevated concentrations of nitric oxide, nitrogen dioxide, and carbon monoxide — had higher incidence of painful periods. (Frontiers in Public Health)

Could obesity soon be the main driver of cancer in the U.S.? (USA Today)

University of California San Diego researchers are set to receive $3 million to thwart childhood obesity in the Latino population. (The Coast News)